Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1.
de With M, van Doorn L, Kloet E, van Veggel A, Matic M, de Neijs MJ, Oomen-de Hoop E, van Meerten E, van Schaik RHN, Mathijssen RHJ, Bins S. de With M, et al. Clin Pharmacokinet. 2023 Nov;62(11):1589-1597. doi: 10.1007/s40262-023-01279-7. Epub 2023 Sep 16. Clin Pharmacokinet. 2023. PMID: 37715926 Free PMC article.
Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD.
de With M, van Doorn L, Maasland DC, Mulder TAM, Oomen-de Hoop E, Mostert B, Homs MYV, El Bouazzaoui S, Mathijssen RHJ, van Schaik RHN, Bins S. de With M, et al. Biomed Pharmacother. 2023 Mar;159:114232. doi: 10.1016/j.biopha.2023.114232. Epub 2023 Jan 9. Biomed Pharmacother. 2023. PMID: 36630849 Free article.
The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer.
Belderbos BPS, de With M, Singh RK, Agema BC, El Bouazzaoui S, Oomen-de Hoop E, de Wit R, van Schaik RHN, Mathijssen RHJ, Bins S. Belderbos BPS, et al. Among authors: de wit r, de with m. Cancer Chemother Pharmacol. 2020 Mar;85(3):547-553. doi: 10.1007/s00280-019-04011-0. Epub 2020 Jan 1. Cancer Chemother Pharmacol. 2020. PMID: 31893292 Clinical Trial.
UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients.
Hulshof EC, de With M, de Man FM, Creemers GJ, Deiman BALM, Swen JJ, Houterman S, Koolen SLW, Bins S, Thijs AMJ, Laven MMJ, Hövels AM, Luelmo SAC, Houtsma D, Shulman K, McLeod HL, van Schaik RHN, Guchelaar HJ, Mathijssen RHJ, Gelderblom H, Deenen MJ. Hulshof EC, et al. Among authors: de with m, de man fm. Eur J Cancer. 2022 Feb;162:148-157. doi: 10.1016/j.ejca.2021.12.009. Epub 2022 Jan 5. Eur J Cancer. 2022. PMID: 34998046 Free article.
DPYD*7 as a Predictor of Severe Fluoropyrimidine-Related Adverse Events.
de With M, Brufau G, van den Berg LA, de Man FM, Trajkovic M, Thijs MF, Castel R, Vermeer HJ, El Bouazzaoui S, van Hemel A, Matic M, Mathijssen RHJ, Bins S, van Schaik RHN. de With M, et al. JCO Precis Oncol. 2022 Jul;6:e2200180. doi: 10.1200/PO.22.00180. JCO Precis Oncol. 2022. PMID: 35862869
CYP3A4∗22 Genotyping in Clinical Practice: Ready for Implementation?
Mulder TAM, van Eerden RAG, de With M, Elens L, Hesselink DA, Matic M, Bins S, Mathijssen RHJ, van Schaik RHN. Mulder TAM, et al. Among authors: de with m. Front Genet. 2021 Jul 8;12:711943. doi: 10.3389/fgene.2021.711943. eCollection 2021. Front Genet. 2021. PMID: 34306041 Free PMC article. Review.
Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer.
Heersche N, Veerman GDM, de With M, Bins S, Assaraf YG, Dingemans AC, van Schaik RHN, Mathijssen RHJ, Jansman FGA. Heersche N, et al. Among authors: de with m. Drug Resist Updat. 2022 May;62:100832. doi: 10.1016/j.drup.2022.100832. Epub 2022 Apr 5. Drug Resist Updat. 2022. PMID: 35427871 Free article. Review.
Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients: Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism?
Hulshof EC, de With M, Creemers GJ, Guchelaar HJ, Mathijssen RH, Gelderblom H, Deenen MJ. Hulshof EC, et al. Among authors: de with m. Eur J Cancer. 2022 Sep;172:231-233. doi: 10.1016/j.ejca.2022.05.045. Epub 2022 Jul 3. Eur J Cancer. 2022. PMID: 35793611 No abstract available.
51 results